Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Personalized Care from Your Local Primary Care Team Your weight loss journey with us begins with a comprehensive evaluation
If you experience side effects: Common temporary effects may include nausea, fatigue, or digestive changes
Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States
Clinical Trial Insights In SURMOUNT-1 and SURPASS trials, Mounjaro showed: Up to 22.5% body weight reduction in non-diabetic obese patients Greater HbA1c reductions vs Ozempic and insulin in diabetics Reference : Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Reference : mounjaro.lilly.com/hcp/a1c-weight FDA approved Mounjaro for Type 2 Diabetes in 2022, and later for weight loss under the brand Zepbound in Nov 2023 (US)
Systemic symptoms, including malaise, fever and headache, may also be present in some patients
Peptide Therapy Targeted peptide protocols for enhanced recovery, longevity, and cellular regeneration
